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 artrite  reumatoide  e  a  síndrome  metabólicacientiﬁc research on rheumatoid arthritis (RA) led to the
rafting of recommendations on early diagnosis of articular
anifestations, appropriate measurements of inﬂammatory
ctivity and bone damage, and target-based treatment, which
ere consolidated in similar guidelines from various organiza-
ions such as the Sociedade Brasileira de Reumatologia (SBR),
he American College of Rheumatology (ACR) and the Euro-
ean League Against Rheumatism (EULAR).1–4 To the extent
hat the treatment strategies of joint manifestations have
xpanded in terms of options and effectiveness, a greater
oncern has arisen about associated diseases, particularly
ardiovascular disease (CVD), which became the main respon-
ible for the decrease of survival in this population, despite
igniﬁcant advances in drug therapy.5–7
Currently, an earlier investigation and monitoring of tradi-
ional risk factors for CVD is recommended, since its presence
s associated with an increased clinical activity of RA, with a
orse prognosis, and with doubling of CVD risk.8–13
The chronic inﬂammatory state, coupled with limited
obility, a sedentary lifestyle and the use of Nonsteroidal anti-
nﬂammatory drugs (NSAIDs) and corticosteroids, determines
he activation of several harmful mechanisms for circulation
nd also increases the predisposition to metabolic syndrome
MS).7,8,11,14
RA and MS share pathogenic mechanisms, for example,
n increase in free radicals, a deﬁciency of antioxidant sys-
ems, an increase in pro-inﬂammatory cytokines, endothelial
njury, and the formation and destabilization of atheroscle-
otic plaques.8,9,15
The concept of MS  arose in the 1980s, encompassing central
besity, dyslipidemia, systemic hypertension and hyper-
lycemia/insulin resistance as elements that are enhanced
nd that, together, offer a higher risk of CVD than the sum of
ndividual factors. The literature has evolved with the study
f MS in different populations, until the proposition of uniﬁed
riteria in 2009.16,17Although the identiﬁcation of MS  in patients with RA is
ery variable, depending on the populations studied and the
lassiﬁcation criteria used, its prevalence has increased anddetermines an additional risk of CVD.5,15,18 A better knowl-
edge of the prevalence of MS and its associations in different
groups of patients results in subsidies to improve preventive
strategies.
In this issue, Oliveira et al. evaluated the occurrence of
MS in patients with RA followed in a university hospital in
northeastern Brazil. In this sample, with large female predom-
inance, more  than half of the patients fulﬁlled different MS
criteria. In addition to obesity, present in almost all patients
with MS, there was an association with other risk factors, such
as age and smoking.19 These ﬁndings point to a high risk of
CVD and increased mortality.
The scientiﬁc community still discuss whether the assess-
ment for risk of CVD should be carried out by instruments used
in the general population, or by tools adapted for RA, to enable
a more  reliable risk assessment, in order to reduce morbidity
and mortality.20,21
With this goal, de Campos et al. tested a tool for prediction
of cardiovascular events, modiﬁed for use in patients with RA
– the mSCORE index. The study evaluated 100 female subjects
with RA versus controls without the disease; it was observed
that there was no difference between groups with respect to
the results of the original SCORE index. However, with the use
of mSCORE version, which includes factors speciﬁc to the dis-
ease, a 3-fold increase in the number of subjects classiﬁed as
of high risk was found, thus becoming clear the increased risk
of the occurrence of a 10-year fatal cardiovascular event in
patients with RA.22
This study emphasizes the fact that, during a systematic
evaluation of patients with RA, an evaluation of cardiovascu-
lar risk must also be carried out. Moreover, this assessment
should be performed with valid instruments, allowing the
identiﬁcation of the risk of CVD and pointing to therapeutic
targets, in order to perform earlier and more  efﬁcient inter-
ventions.
In this way, one can make a better use of the acknowledged
advances in the treatment of joint disease in these patients,
in order to obtain, for them, a better and long-lasting health
condition.
 t o l .
r
1
1
1
1
1
1
1
1
1
1
2
2
2
E-mail: a.assismr@gmail.com (M.R. Assis).94  r e v b r a s r e u m a
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. da Mota LMH, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza
LS, Bertolo MB, et al. Consenso da Sociedade Brasileira de
Reumatologia 2011 para o diagnóstico e avaliac¸ão inicial da
artrite reumatoide. Rev Bras Reumatol. 2011;51:
207–19.
2. da Mota LMH, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza
LS, Bertolo MB, et al. Consenso 2012 da Sociedade Brasileira
de Reumatologia para o tratamento da artrite reumatoide.
Rev Bras Reumatol. 2012;52:135–74.
3. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P,
Gaujoux-Viala C, et al. EULAR recommendations for the
management of rheumatoid arthritis with synthetic and
biological disease-modifying antirheumatic drugs: 2013
update. Ann Rheum Dis. 2013,
http://dx.doi.org/10.1136/annrheumdis-2013-204573.
4.  Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan
MC,  et al. 2015 American College of Rheumatology Guideline
for the Treatment of Rheumatoid Arthritis. Arthritis Care Res.
2015, http://dx.doi.org/10.1002/acr.22783.
5.  Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA,
Manson JE, et al. Cardiovascular morbidity and mortality in
women diagnosed with rheumatoid arthritis. Circulation.
2003;107:1303–7.
6. Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis
JM  3rd, Therneau TM, et al. The widening mortality gap
between rheumatoid arthritis patients and the general
population. Arthritis Rheum. 2007;56:3583–7.
7. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis.
Best Pract Res Clin Rheumatol. 2007;21:885–906.
8. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani
A,  et al. Prevalence of the metabolic syndrome is increased in
rheumatoid arthritis and is associated with coronary
atherosclerosis. Atherosclerosis. 2008;196:756–63.
9. Giles JT, Allison M, Blumenthal RS, Post W,  Gelber AC, Petri M,
et  al. Abdominal adiposity in rheumatoid arthritis:
association with cardiometabolic risk factors and disease
characteristics. Arthritis Rheum. 2010;62:3173–82.
0. Peters MJ. EULAR evidence-based recommendations for
cardiovascular risk management in patients with rheumatoid
arthritis and other forms of inﬂammatory arthritis. Ann
Rheum Dis. 2010;69:325–31.
1. Cunha VR, Brenol CV, Brenol JC, Xavier RM. Artrite reumatóide
e  síndrome metabólica. Rev Bras Reumatol. 2011;51:260–8.
2. Pereira IA, da Mota LM, Cruz BA, Brenol CV, Rezende-Fronza
LS,  Bertolo MB, et al. Consenso 2012 da Sociedade Brasileira
de Reumatologia sobre o manejo de comorbidades em 2 0 1 6;5 6(2):93–94
pacientes com o diagnóstico de Artrite Reumatoide. Rev Bras
Reumatol. 2012;52:474–95.
3. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z,
Nurmohamed M. Cardiovascular risk in rheumatoid arthritis:
recent advances in the understanding of the pivotal role of
inﬂammation, risk predictors and the impact of treatment.
Rheumatology. 2014;53:2143–54.
4. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M.
Glucocorticoids and insulin sensitivity in rheumatoid
arthritis. J Rheumatol. 2004;31:867–74.
5. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A.
High incidence of cardiovascular events in a rheumatoid
arthritis cohort not explained by traditional cardiac risk
factors. Arthritis Rheum. 2001;44:2737–45.
6. Reaven GM. Banting lecture 1988. Role of insulin resistence in
human disease. Diabetes. 1988;37:1595–607.
7. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI,
Donato KA, et al. Harmonizing the metabolic syndrome. A
joint  interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention;
National Heart, Lung and Blood Institute; American Heart
Association; World Heart Federation; International
Atherosclerosis Society; and International Association for the
Study of Obesity. Circulation. 2009:1640–5.
8. Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B, et al. The risk of
metabolic syndrome in patients with rheumatoid arthritis: a
meta-analysis of observational studies. PLOS ONE.
2013;8:e78151.
9. Oliveira BMGB, Medeiros MM, Cerqueira JV, Quixadá RT,
Oliveira ÍM. Metabolic syndrome in patients with rheumatoid
arthritis followed at a university hospital in Northeastern
Brazil. Rev Bras Reumatol. 2016;56:117–25.
0. Symmons DP. Do we need a disease-speciﬁc cardiovascular
risk calculator for patients with rheumatoid arthritis?
Arthritis Rheumatol. 2015;67:1990–4.
1. Hollan I, Dessein PH, Ronda N, Wasko MC, Svenungsson E,
Agewall S, et al. Prevention of cardiovascular disease in
rheumatoid arthritis. Autoimmun Rev. 2015;14:952–69.
2. de Campos OAM, Nazário NO, de Magalhães Souza Fialho SC,
Fialho GL, de Oliveira FJS, de Castro GRW, et al. Assessment of
cardiovascular risk in patients with rheumatoid arthritis
using the SCORE risk index. Rev Bras Reumatol.
2016;56:138–44.
Marcos Renato de Assisa,b,∗, Patrícia Amanda Seraﬁma
a Faculdade de Medicina de Marília (Famema), Marília, SP, Brazil
b Editor-in-Chief, Revista Brasileira de Reumatologia, Brazil
∗ Corresponding author.http://dx.doi.org/10.1016/j.rbre.2016.02.015
2255-5021/© 2016 Elsevier Editora Ltda. All rights reserved.
